SIRTURO® (bedaquiline) Is a First-in-Class ATP Synthase Inhibitor for Pulmonary Multi-drug Resistant TB (MDR-TB)

SIRTURO® adds a novel mechanism of action to the treatment of pulmonary MDR-TB.

  • SIRTURO® is the first anti-TB drug to interfere with bacterial energy metabolism.5-7 It is mechanistically and structurally unrelated to current first-line agents.2,5,7,8
  • SIRTURO® specifically inhibits mycobacterial ATP (adenosine 5’-triphosphate) synthase, by binding to subunit c of the enzyme that is essential for the generation of energy in Mycobacterium tuberculosis.

SIRTURO Mechanism of Action

Download a comprehensive resource on SIRTURO® (bedaquiline) tablets